ENTL Entelos Regs

    


Entelos Inc.



Entelos, Inc. (LSE:ENTL) a leading life sciences company building predictive
computer models of human physiology and "virtual patients" for drug discovery
and development, announced today that UCB Pharma S.A. ("UCB Pharma") has signed
an agreement with Entelos to conduct in silico research in the field of
rheumatoid arthritis ("RA") using the Entelos(R) Rheumatoid Arthritis
PhysioLab(R) platform. Financial terms were not disclosed.

The Entelos Rheumatoid Arthritis PhysioLab platform is an innovative and
predictive computer model that simulates arthritic patients and drug effects and
it has already been used successfully with other pharmaceutical partners to
select targets and compounds, find the best doses for patients, and support
clinical trial design.

"We are pleased to add UCB Pharma to our list of new customers," commented James
Karis, president and CEO of Entelos. "We believe that our RA PhysioLab platform
enables more rapid assessment, evaluation, and testing of complex therapies in
this chronic, debilitating disease that is most difficult to treat. We look
forward to a productive and rewarding relationship with UCB in the years to
come."

For further information please contact:

Entelos, Inc.
James Karis, President and CEO                    Tel: +1 650 572 5400
Jill Fujisaki, VP Investor Relations

Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson             Tel +44 (0) 20 7466 5000

Notes for Editors

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual patients", and toxicology reference systems to
develop safer and more effective drugs and support pharmaceutical R&D and
commercialization. In addition to internal drug programs in rheumatoid arthritis
and women's health, Entelos provides customized technology and research services
to global pharmaceutical and health-care companies in cardiovascular diseases,
asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and
skin sensitization. The company is also developing a model in oncology and is
collaborating with the FDA to build a model of drug-induced liver injury.
Entelos offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys.

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024